Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain

Objective: Splenectomy, thrombopoietin receptor agonists and rituximab are the second-line treatments for steroid-resistant adult primary immune thrombocytopenia. The last two are becoming the most widely used treatments to avoid splenectomy adverse effects and inconveniences. However, the choice...

Full description

Saved in:
Bibliographic Details
Main Authors: Eduardo Anguita, Francisco Javier Parrondo García, José Ramón González-Porras
Format: Artigo
Language:Inglês
Published: Grupo Aula Médica 2020-11-01
Series:Farmacia Hospitalaria
Subjects:
pharmacoeconomics
hematologic agents
hematologic diseases
cost analysis
immune thrombocytopenia
thrombopoietin receptor agonists
eltrombopag
rituximab
Online Access:http://www.aulamedica.es/fh/pdf/11525.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items